In clinical research, few words carry more operational risk than “ready.”
A site may be described as ready when a Research Ethics Committee or Institutional Review Board has approved the protocol. A network may be described as ready when a master agreement is in place. A country may be described as ready when the national regulatory authority has authorized the study. Each of these milestones matters. None, on its own, proves that a trial can be executed reliably.
This distinction is not semantic. It is operational.
When readiness is declared too early, implementation challenges may later be attributed to geography, context, or site performance, when the more precise explanation is often that execution readiness was not fully tested. In African clinical research, where the stakes of trust, perception, and delivery are especially high, the word “ready” must be used with more discipline.
Trial readiness is not an approval status. It is the demonstrated ability of a site, team, and surrounding system to deliver a specific protocol safely, ethically, consistently, and to the required quality standard.
Approval, qualification, and execution are not the same
One reason readiness is poorly defined is that several different milestones often collapse into one word.
Authorization readiness means that the necessary ethics and regulatory approvals are in place. This is essential, but it only confirms that the study may proceed. It does not confirm that the site can deliver the study well.
Qualification readiness means that a site appears suitable based on feasibility assessment, prior experience, available facilities, investigator credentials, and sponsor or contract research organization review. This is important, but it is still largely a pre-execution judgment.
Execution readiness is different. It asks whether the site, team, systems, workflows, participants, suppliers, laboratories, data platforms, and escalation pathways are ready for the actual demands of the protocol.
A site can be approved but not operationally ready. It can be qualified but not resilient. It can pass a checklist and still struggle once recruitment, sample movement, pharmacy processes, data entry, monitoring, safety reporting, and staff continuity are tested under real trial conditions.
This is where many studies encounter avoidable difficulty.
The six domains of real readiness
A credible readiness assessment must be protocol-specific. A generic site checklist is not enough.
At minimum, trial readiness should be assessed across six operational domains.
- Research team readiness
The question is not simply whether the principal investigator is experienced or whether a coordinator has completed Good Clinical Practice training. The question is whether the full team can deliver this protocol.
That includes investigator oversight, delegation of duties, coordinator capacity, pharmacy support, laboratory support, data management, safety reporting, backup coverage, current training records, and enough protected time to perform the work. Good Clinical Practice places clear responsibility on investigators and sponsors to protect participants and generate reliable data; those responsibilities cannot be met by names on a delegation log alone (1-3).
A readiness assessment should therefore ask: who will do the work, who will supervise it, who will cover gaps, and what happens if a key person leaves?
- Infrastructure readiness
Infrastructure readiness is more than having a clinic room and a lockable cabinet.
A protocol may require cold-chain storage, calibrated equipment, sample processing within defined time windows, reliable internet, controlled document storage, investigational product accountability, participant privacy, backup power, and transport arrangements. These requirements differ by study.
A site that is ready for an observational cohort may not be ready for an early-phase interventional trial. A site that is ready for a low-intensity follow-up study may not be ready for a protocol requiring frequent visits, intensive laboratory processing, or rapid safety escalation.
Readiness must therefore be assessed against the actual protocol, not the site’s general reputation.
- Study management readiness
Many trials fail not because the science is weak, but because the operational model is underdeveloped.
Study management readiness includes start-up planning, visit scheduling, participant tracking, screening logs, source documentation, delegation, filing systems, vendor coordination, site communication, issue escalation, and timeline management.
The protocol is not only a scientific document. It is also an operating manual. Contemporary protocol guidance such as SPIRIT emphasizes the importance of clarity in trial design, procedures, outcomes, safety reporting, and implementation details (4). If the protocol is the operating manual, readiness is the process of checking whether the site can actually operate it.
- Data collection and data management readiness
Data quality is not rescued at the end of a trial. It is built from the beginning.
A site is not ready if staff do not understand the case report forms, source documentation requirements, data entry timelines, query-resolution expectations, data protection obligations, and electronic data capture systems.
Data readiness should include user access, training, source-to-database workflows, quality checks, query management, and clarity on who is accountable for each step. Risk-based monitoring guidance emphasizes that oversight should focus on critical data and processes that matter most for participant protection and reliable results (5). That requires the data pathway to be understood before enrollment begins.
- Quality oversight readiness
Quality is not the same as inspection readiness. It is the ability to detect, correct, and prevent problems during the life of a study.
A readiness assessment should examine whether the site has a quality management approach proportionate to the risk and complexity of the trial. This includes deviation management, corrective and preventive action processes, internal review, monitoring follow-up, documentation practices, and escalation pathways.
The most important question is not whether a site can appear ready on the day of selection. It is whether the site can stay ready as the protocol becomes operational.
- Ethics and safety readiness
Ethics approval is not the end of ethical readiness. It is the beginning.
A site must be ready to consent participants properly, protect confidentiality, identify and report adverse events, escalate serious safety concerns, manage protocol deviations, communicate with the ethics committee and regulator where required, and protect participants throughout the study.
This is especially important in complex or multi-site trials where safety information, laboratory findings, investigational product accountability, and participant follow-up may move across several systems. Ethical readiness therefore depends on operational readiness.
What conventional readiness assessments often miss
Most readiness assessments are strongest at documenting what exists on a given day. They are weaker at testing whether the system can perform under pressure.
Three areas are often under-assessed.
- Workforce resilience
A site may pass a readiness checklist and then lose the coordinator who built the checklist three months later. That is not a small operational detail. In many clinical trials, coordinators, nurses, pharmacists, laboratory staff, data officers, and research administrators carry much of the execution burden.
Readiness should therefore include workforce stability, role coverage, succession planning, training records, workload, supervision, and retention risk.
The question is not only, “Do you have the staff?”
It is, “Can this team remain functional for the duration of the trial?”
- Patient-flow stress testing
Feasibility is often treated as an estimate. It should be treated as a stress test.
A protocol-specific patient-flow assessment should compare recruitment assumptions against real clinic volumes, referral pathways, screening criteria, expected screen-failure rates, visit schedules, pharmacy capacity, laboratory turnaround times, participant transport needs, and follow-up requirements.
This matters because trial failure is often linked to practical issues such as recruitment, retention, protocol complexity, and operational feasibility (6). A site may have access to the right patient population in theory, but still be unable to move participants through the protocol reliably in practice.
The better question is not, “How many patients do you see?”
It is, “How many eligible participants can realistically be screened, consented, enrolled, followed, sampled, documented, and retained under this protocol?”
- System-level readiness
A site can be ready while the system around it is not.
Clinical trials depend on more than investigators and clinic rooms. They depend on ethics timelines, regulatory pathways, import permits, customs clearance, investigational product supply, central laboratories, sample transport, monitoring systems, data platforms, insurance, contracts, finance processes, and escalation routes.
If these systems are weak, the site will carry the consequences, even when the site itself has done its part.
This is why readiness should be assessed at three levels: site, network, and system.
Readiness is continuous, not one-time
One of the most common mistakes in clinical trial start-up is treating readiness as a gate that is crossed once.
In reality, readiness changes.
Staff leave. Clinic volumes shift. Equipment fails. Internet systems go down. Regulatory requirements evolve. Competing studies open. Participant pathways change. Central laboratory arrangements are delayed. Queries accumulate. Monitoring findings reveal patterns that were not visible at initiation.
A site that was ready at selection may not remain ready six months later unless readiness is actively maintained.
That is why trial readiness should include periodic reassessment. The aim is not to create bureaucracy. It is to detect risk early enough to protect participants, data quality, timelines, and trust.
What other systems demonstrate
Other research ecosystems show that readiness becomes stronger when site capability is supported by system-level infrastructure.
Singapore offers a useful example, not because its model can be copied directly, but because it illustrates the value of coordinated clinical research systems. The Singapore Clinical Research Institute describes itself as the country’s national academic clinical research organization and supports functions such as project management, data management, trial monitoring, biostatistics, clinical research networks, and a master clinical trial agreement (7, 8).
Its master clinical trial agreement is particularly relevant because it recognizes that clinical trial start-up involves more than site selection. It includes agreement negotiation, ethics review, regulatory approval, and site start-up. By pre-negotiating certain terms across public healthcare clusters and industry partners, the system attempts to reduce predictable delays in contracting (7).
The lesson is not that Africa should replicate Singapore. The lesson is that readiness improves when institutions invest in the substrate around trials: agreements, networks, data systems, quality functions, trained people, and operational coordination.
Readiness is institutional. It is not merely project-based.
What African trial readiness should look like
For African clinical research to compete on quality, speed, and trust, readiness must become more explicit and more measurable.
A credible African readiness model should include at least five components.
First, a protocol-specific readiness rubric that assesses the research team, infrastructure, study management, data systems, quality oversight, and ethics and safety.
Second, a workforce readiness component that looks at coordinator stability, investigator oversight, training records, role coverage, succession planning, and staff workload.
Third, a patient-flow stress test that uses real clinic data and referral pathways rather than optimistic recruitment estimates.
Fourth, a system-level readiness assessment that examines contracts, ethics timelines, regulatory processes, import permits, sample logistics, central laboratories, data platforms, monitoring arrangements, and escalation pathways.
Fifth, a readiness evidence base that allows networks to track where delays occur, which assumptions were wrong, and which investments improve performance over time.
This would move the conversation from anecdote to evidence.
It would also make readiness a shared responsibility. Sponsors, contract research organizations, investigators, networks, regulators, ethics committees, laboratories, and funders all shape whether a trial can start well and remain on track.
What ACRN takes seriously
At tACRN, we are working toward a readiness approach that is explicit, auditable, and protocol-specific.
The aim is not to make readiness harder for its own sake. The aim is to ensure that when a site, team, or system is described as ready, that statement reflects real execution capacity.
That means asking more disciplined questions.
Can this team deliver the protocol safely?
Can the site manage the data pathway?
Can the pharmacy and laboratory meet protocol requirements?
Can participants realistically move through the visit schedule?
Are safety reporting processes clear?
Are monitoring and quality systems in place?
Are contracts, approvals, import permits, sample logistics, and escalation pathways aligned?
These questions may seem operational, but they are strategic. They determine whether African clinical research is experienced by sponsors, regulators, investigators, and participants as reliable, ethical, and globally competitive.
The patient at the Centre of any trial deserves a site that is genuinely ready.
The investigator deserves a system that does not set the team up to fail.
The sponsor deserves a partner whose readiness is more than a document.
And the continent deserves a clinical research narrative built on evidence, not assumption.
The word “ready” is doing too much work in clinical research. The work of the next decade is to make sure we deserve it.
References
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Harmonised Guideline E8(R1): General Considerations for Clinical Studies. International Council for Harmonisation (ICH); 2021. Report No.: E8(R1).
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Harmonised Guideline E6(R3): Guideline for Good Clinical Practice. International Council for Harmonisation (ICH); 2025. Report No.: E6(R3).
- U.S. Food and Drug Administration. Guidance for Industry: Investigator Responsibilities—Protecting the Rights, Safety, and Welfare of Study Subjects. U.S. Food and Drug Administration; 2009.
- Chan A-W, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, et al. SPIRIT 2025 statement: updated guideline for protocols of randomized trials. Nature Medicine. 2025;31(6):1784–92.
- U.S. Food and Drug Administration. Guidance for Industry: Oversight of Clinical Investigations—A Risk-Based Approach to Monitoring. U.S. Food and Drug Administration; 2013.
- Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contemp Clin Trials Commun. 2018;11:156–64.
- (SCRI) SCRI. Master Clinical Trial Agreement 2026 [Available from: https://www.scri.edu.sg/national-coordinating-body/master-clinical-trial-agreement/.
- (SCRI) SCRI. About SCRI 2026 [Available from: https://www.scri.edu.sg/about-us/about-scri/.